<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>24(9)</volume><submitter>Simon JA</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>To evaluate the response of the vaginal mucosa with TX-004HR and its correlation with vulvar and vaginal atrophy (VVA) symptoms, and whether visual examination is a useful measure for assessing VVA.&lt;h4>Methods&lt;/h4>REJOICE was a 12-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study of a vaginal, muco-adhesive, 17β-estradiol softgel capsule (TX-004HR 4, 10, and 25 μg) in postmenopausal women with VVA and moderate-to-severe dyspareunia. Treatments were self-administered vaginally once per day for 2 weeks, then twice per week for 10 weeks. The vagina was visually examined at baseline and at weeks 2, 6, 8, and 12; changes were evaluated using a 4-item scale for vaginal color, vaginal epithelial integrity, vaginal epithelial surface thickness, and va</pubmed_abstract><journal>Menopause (New York, N.Y.)</journal><pagination>1003-1010</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5571882</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.</pubmed_title><pmcid>PMC5571882</pmcid><pubmed_authors>Kagan R</pubmed_authors><pubmed_authors>Archer DF</pubmed_authors><pubmed_authors>Graham S</pubmed_authors><pubmed_authors>Bernick B</pubmed_authors><pubmed_authors>Mirkin S</pubmed_authors><pubmed_authors>Constantine GD</pubmed_authors><pubmed_authors>Simon JA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.</name><description>&lt;h4>Objective&lt;/h4>To evaluate the response of the vaginal mucosa with TX-004HR and its correlation with vulvar and vaginal atrophy (VVA) symptoms, and whether visual examination is a useful measure for assessing VVA.&lt;h4>Methods&lt;/h4>REJOICE was a 12-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study of a vaginal, muco-adhesive, 17β-estradiol softgel capsule (TX-004HR 4, 10, and 25 μg) in postmenopausal women with VVA and moderate-to-severe dyspareunia. Treatments were self-administered vaginally once per day for 2 weeks, then twice per week for 10 weeks. The vagina was visually examined at baseline and at weeks 2, 6, 8, and 12; changes were evaluated using a 4-item scale for vaginal color, vaginal epithelial integrity, vaginal epithelial surface thickness, and va</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Sep</publication><modification>2026-05-01T15:06:59.101Z</modification><creation>2025-05-29T16:29:15.086Z</creation></dates><accession>S-EPMC5571882</accession><cross_references><pubmed>28419068</pubmed><doi>10.1097/GME.0000000000000880</doi></cross_references></HashMap>